FOLH1 and posterior cortical atrophy: In addition to PSMA and GRPR, numerous alternative molecular targets have been explored for PCa imaging and therapy using 64Cu-labeled radiopharmaceuticals, each offering unique biological rationales and translational potential (Tables 6 and 7).